What is the prevalence of Endometrial cancer?

Endometrial cancer is the most common gynecologic malignancy in developed countries, with an estimated prevalence of over 800,000 women currently living with the condition in the United States alone. While it is considered a common cancer rather than a rare disease, accurate global prevalence data remains challenging to track due to variations in regional cancer registries and potential underreporting of early-stage cases.

What is the annual incidence of Endometrial cancer?

According to the American Cancer Society, there are approximately 67,000 new cases of Endometrial cancer diagnosed annually in the U.S. Globally, incidence rates vary significantly, often correlating with lifestyle factors, obesity rates, and access to reproductive healthcare. Because Endometrial cancer often presents with postmenopausal bleeding, many cases are caught early, though asymptomatic or misdiagnosed instances can lead to discrepancies in recorded incidence statistics.

Who is most affected by Endometrial cancer?

Endometrial cancer occurs almost exclusively in individuals with a uterus. It is predominantly a disease of postmenopausal women, with the average age of diagnosis being approximately 60 years. While rare in younger populations, it can occur in individuals under 40, often associated with genetic predispositions like Lynch syndrome.

Are there geographic or ethnic variations in Endometrial cancer?

Research indicates notable disparities in the diagnosis and outcomes of Endometrial cancer, which are critical for patients to understand:

• Incidence: Higher rates are observed in North America and Europe compared to parts of Asia and Africa.


• Mortality: Black women in the United States face a higher mortality rate from Endometrial cancer, often due to a higher prevalence of aggressive histological subtypes.


• Community Insights: On DiseaseMaps.org, 31 members have joined the community, providing a vital, real-world perspective on the diverse experiences of living with this condition.

What challenges exist in tracking Endometrial cancer data?

While Endometrial cancer is well-documented, true prevalence is difficult to determine because some cases may be misclassified or underreported in regions with limited screening infrastructure. As an epidemiologist, I emphasize that these numbers are estimates; localized health data is essential for understanding the true burden of Endometrial cancer in specific populations.

Next steps

• Consult a gynecologic oncologist to discuss your specific risk factors and screening needs.


• Join the Endometrial cancer community on DiseaseMaps.org to share experiences with others.


• Maintain regular check-ups with your healthcare provider, especially if you experience abnormal uterine bleeding.

Medical disclaimer: This information is for educational purposes only and does not replace professional medical advice, diagnosis, or treatment.

References

• American Cancer Society: Cancer Facts & Figures 2024.


• National Cancer Institute (NCI) SEER Program: Cancer Stat Facts.


• World Health Organization (WHO) GLOBOCAN database.


• NIH Genetic and Rare Diseases (GARD) Information Center.